Seward moves to new premises
Doubles manufacturing and storage facilities
The new building represents a significant investment by the company following the securing of a NatWest/RBS Manufacturing Fund. It will also ensure shorter lead times for the Stomacher sample preparation products for microbiological analyses and tissue processing, the company said.
The premises also house a purpose-built r&d laboratory for product development, application assessment and customer protocol development.
Further investment in web conferencing facilities will also allow training webinars and in-depth technical support to be offered to customers, wherever they are located.
The new premises support a much-needed increase in production capacity, driven by new applications and the opening of Seward Inc in Long Island, New York, US in 2009.
In the first half of 2010, sales of the Stomacher laboratory blenders grew by nearly 20%, compared with the same period in 2009. Sales of the Stomacher 80 biomaster range for small tissue processing increased by 53%, while the large volume Stomacher 3500 saw a 72% growth.
‘We are dedicated to maintaining excellence in our products, customer service and support for our rapidly growing global customer base, so the increased size and capacity of our new premises ensures we can guarantee this now and in the future,’ said Stuart Ray, technical director, Seward Ltd.
He added that the firm had also seen strong growth in the US and Asia/Pacific regions.
You may also like
Trending Articles
You may also like
Manufacturing
Virica Biotech and FUJIFILM Biosciences collaborate to boost AAV vector yields in HEK293 manufacturing system
Virica Biotech has announced a collaboration with FUJIFILM Biosciences to co-develop an off-the-shelf enhancer-media solution combining Virica's VSE technology with FUJIFILM's BalanCD HEK293 system, targeting improved AAV productivity and process robustness for gene therapy manufacturers
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Accelerating the development of bispecific antibodies
Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market
Manufacturing
Nemera partners with Therakind to expand nasal drug delivery portfolio with DriDose dry powder platform
The manufacturer has announced a strategic partnership with UK pharmaceutical company Therakind to advance the DriDose intranasal dry powder platform, adding dry powder delivery capabilities to complement Nemera's existing liquid nasal formulation offering